Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
Mitsubishi Estate Co is expanding its Australian footprint, adding Sydney’s $2.3-billion Harbourside redevelopment to a portfolio approaching $18 billion. In an equal partnership with Mirvac, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback